Browse GUCY1B3

Summary
SymbolGUCY1B3
Nameguanylate cyclase 1, soluble, beta 3
Aliases GC-SB3; GC-S-beta-1; GUC1B3; GUCB3; GUCSB3; GUCY1B1; GCS-beta-1; GCS-beta-3; guanylate cyclase soluble subun ......
Chromosomal Location4q31.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF00211 Adenylate and Guanylate cyclase catalytic domain
PF07700 Haem-NO-binding
PF07701 Heme NO binding associated
Function

Mediates responses to nitric oxide (NO) by catalyzing the biosynthesis of the signaling molecule cGMP.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0003013 circulatory system process
GO:0006164 purine nucleotide biosynthetic process
GO:0006182 cGMP biosynthetic process
GO:0006979 response to oxidative stress
GO:0007263 nitric oxide mediated signal transduction
GO:0008015 blood circulation
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0010035 response to inorganic substance
GO:0019932 second-messenger-mediated signaling
GO:0019934 cGMP-mediated signaling
GO:0019935 cyclic-nucleotide-mediated signaling
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0038060 nitric oxide-cGMP-mediated signaling pathway
GO:0046068 cGMP metabolic process
GO:0046390 ribose phosphate biosynthetic process
GO:0052652 cyclic purine nucleotide metabolic process
GO:0071241 cellular response to inorganic substance
GO:0071731 response to nitric oxide
GO:0071732 cellular response to nitric oxide
GO:0072522 purine-containing compound biosynthetic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1902170 cellular response to reactive nitrogen species
Molecular Function GO:0004383 guanylate cyclase activity
GO:0005525 GTP binding
GO:0009975 cyclase activity
GO:0016829 lyase activity
GO:0016849 phosphorus-oxygen lyase activity
GO:0019001 guanyl nucleotide binding
GO:0020037 heme binding
GO:0032561 guanyl ribonucleotide binding
GO:0046906 tetrapyrrole binding
Cellular Component GO:0008074 guanylate cyclase complex, soluble
GO:0044445 cytosolic part
> KEGG and Reactome Pathway
 
KEGG hsa04022 cGMP-PKG signaling pathway
hsa04270 Vascular smooth muscle contraction
hsa04540 Gap junction
hsa04611 Platelet activation
hsa04713 Circadian entrainment
hsa04730 Long-term depression
hsa04921 Oxytocin signaling pathway
hsa04970 Salivary secretion
hsa00230 Purine metabolism
Reactome R-HSA-109582: Hemostasis
R-HSA-392154: Nitric oxide stimulates guanylate cyclase
R-HSA-418346: Platelet homeostasis
Summary
SymbolGUCY1B3
Nameguanylate cyclase 1, soluble, beta 3
Aliases GC-SB3; GC-S-beta-1; GUC1B3; GUCB3; GUCSB3; GUCY1B1; GCS-beta-1; GCS-beta-3; guanylate cyclase soluble subun ......
Chromosomal Location4q31.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GUCY1B3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolGUCY1B3
Nameguanylate cyclase 1, soluble, beta 3
Aliases GC-SB3; GC-S-beta-1; GUC1B3; GUCB3; GUCSB3; GUCY1B1; GCS-beta-1; GCS-beta-3; guanylate cyclase soluble subun ......
Chromosomal Location4q31.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GUCY1B3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGUCY1B3
Nameguanylate cyclase 1, soluble, beta 3
Aliases GC-SB3; GC-S-beta-1; GUC1B3; GUCB3; GUCSB3; GUCY1B1; GCS-beta-1; GCS-beta-3; guanylate cyclase soluble subun ......
Chromosomal Location4q31.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GUCY1B3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7460.0353
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0260.289
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5470.511
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5380.145
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6920.639
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3490.843
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5230.302
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4260.719
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6530.61
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7970.556
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2310.563
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1640.185
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GUCY1B3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.75.5-1.81
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.76.8-3.11
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGUCY1B3
Nameguanylate cyclase 1, soluble, beta 3
Aliases GC-SB3; GC-S-beta-1; GUC1B3; GUCB3; GUCSB3; GUCY1B1; GCS-beta-1; GCS-beta-3; guanylate cyclase soluble subun ......
Chromosomal Location4q31.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GUCY1B3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGUCY1B3
Nameguanylate cyclase 1, soluble, beta 3
Aliases GC-SB3; GC-S-beta-1; GUC1B3; GUCB3; GUCSB3; GUCY1B1; GCS-beta-1; GCS-beta-3; guanylate cyclase soluble subun ......
Chromosomal Location4q31.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GUCY1B3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GUCY1B3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGUCY1B3
Nameguanylate cyclase 1, soluble, beta 3
Aliases GC-SB3; GC-S-beta-1; GUC1B3; GUCB3; GUCSB3; GUCY1B1; GCS-beta-1; GCS-beta-3; guanylate cyclase soluble subun ......
Chromosomal Location4q31.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GUCY1B3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGUCY1B3
Nameguanylate cyclase 1, soluble, beta 3
Aliases GC-SB3; GC-S-beta-1; GUC1B3; GUCB3; GUCSB3; GUCY1B1; GCS-beta-1; GCS-beta-3; guanylate cyclase soluble subun ......
Chromosomal Location4q31.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GUCY1B3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGUCY1B3
Nameguanylate cyclase 1, soluble, beta 3
Aliases GC-SB3; GC-S-beta-1; GUC1B3; GUCB3; GUCSB3; GUCY1B1; GCS-beta-1; GCS-beta-3; guanylate cyclase soluble subun ......
Chromosomal Location4q31.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GUCY1B3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGUCY1B3
Nameguanylate cyclase 1, soluble, beta 3
Aliases GC-SB3; GC-S-beta-1; GUC1B3; GUCB3; GUCSB3; GUCY1B1; GCS-beta-1; GCS-beta-3; guanylate cyclase soluble subun ......
Chromosomal Location4q31.3-q33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GUCY1B3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.